Small Molecules to Improve ER Proteostasis in Disease

Trends Pharmacol Sci. 2019 Sep;40(9):684-695. doi: 10.1016/j.tips.2019.07.003. Epub 2019 Jul 31.

Abstract

Abnormally high levels of misfolded proteins in the endoplasmic reticulum (ER) lumen result in a stress state that contributes to the progression of several pathological conditions including diabetes, cancer, neurodegeneration, and immune dysregulation. ER stress triggers a dynamic signaling pathway known as the unfolded protein response (UPR). The UPR enforces adaptive or cell death programs by integrating information about the intensity and duration of the stress stimuli. Thus, depending on the disease context, ER stress signaling can be beneficial or detrimental. We discuss current efforts to develop small molecules to target distinct components of the UPR, and their possible applications in treating human disease, focusing on neurodegenerative diseases, metabolic disorders, and cancer.

Keywords: ER stress; ISR; UPR; drug repurposing; proteostasis; small molecules.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Animals
  • Endoplasmic Reticulum / drug effects*
  • Endoplasmic Reticulum / metabolism
  • Humans
  • Metabolic Diseases / drug therapy*
  • Metabolic Diseases / metabolism
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism
  • Neurodegenerative Diseases / drug therapy*
  • Neurodegenerative Diseases / metabolism
  • Proteostasis / drug effects
  • Unfolded Protein Response / drug effects